PORT WASHINGTON, NY – September 26, 2017: Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the following new additions to the Allegro™ single-use chromatography and Cadence™ continuous bioprocessing product portfolios. Each product enables scalable process integration and intensification for biopharmaceutical manufacturers, while drastically reducing resource use, process time, user risk and overall facility footprint. The technologies will be showcased this week in booths #219 and #319 at the BPI 2017 event in Boston, MA.

Allegro Single-Use Chromatography System: The latest addition to the industry’s first complete, automated platform of scalable single-use solutions — R&D to process scale — will be previewed during the BPI event. The flexible single-use chromatography system design enables installation of two different sized manifolds, with a flow range of 10 to 900 L/h. In addition, the system can accommodate applications utilizing membrane chromatography. 

Cadence BioSMB Process 80 System: This modular 80 liter/hour process scale continuous multicolumn chromatography system has been built specifically to support small-scale process development, with perfusion bioreactor-based compatibility.

Cadence BioSMB Process 350 System: This modular 350 liter/hour process scale continuous multicolumn chromatography system allows for scalable process flexibility, while still delivering the advantages of minimized facility footprint and resource consumption. It has been designed for fed-batch applications of up to 2000 L.

Cadence Virus Inactivation System: Designed to complement the Cadence BioSMB Process 80 and 350 systems, this fully-automated low-pH virus inactivation system can be integrated into batch, semi- or fully continuous processes.

“A changing market has increased demand for drug manufacturers to innovate, thereby driving the need for critical automated end-to-end traditional and single-use process solutions. This is especially true as many manufacturers look to pursue the advantages of semi- or fully-continuous bioprocessing approaches,” explained Martin Smith, Pall Chief Technology Officer. “The latest additions to our technology portfolio provide the support manufacturers need, and carry forward Pall’s promise to bring continuous bioprocesses to life. We are happy to introduce these new technologies to the industry during BPI 2017 this week.”

The Pall Life Sciences team is onsite at BPI 2017 through September 28 in booths #219 and #319. To request a meeting during the event, please email biopharm@pall.com. To learn more about how Pall Life Sciences supports the biopharmaceutical industry, please visit www.pall.com/biopharm.

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.


Or follow us on social media: YouTube - LinkedIn - Twitter

Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development